ADRENACLICK (epinephrine) by Fresenius Kabi is adrenergic alpha-agonists [moa]. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
ADRENACLICK is an epinephrine auto-injector indicated for emergency treatment of anaphylaxis and severe allergic reactions. It works as an alpha-adrenergic agonist, rapidly restoring blood pressure and airway patency through sympathomimetic action. The product is delivered via intramuscular or subcutaneous injection for acute, life-threatening situations.
As an approaching LOE product facing moderate competitive pressure (30%), commercial teams should expect market share erosion and potential workforce optimization within 2-3 years.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Worked on ADRENACLICK at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moRoles on ADRENACLICK align primarily with commercial defense and market access rather than growth or innovation. Working on this product offers valuable experience in pricing strategy, competitor response, and patient access programs in a high-pressure LOE environment.